Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Can a tailored stent graft tame complex aortic aneurysms?

NCT ID NCT04526938

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused This study
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Aug 11, 2026 · Last updated Aug 12, 2026 · Updated 1 time

Summary

This trial is testing a specially modified stent graft—a small mesh tube—to repair complex aortic aneurysms in people who are too high-risk for open surgery. The graft is adjusted by the physician to keep blood flowing to the kidneys and other vital organs during the procedure. The study will track safety, how well the repair holds up over a year, and how the treatment affects quality of life.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
A physician-modified Cook Zenith Alpha Thoracic Endovascular Graft, a stent graft device altered to keep blood flowing to vital organs during aneurysm repair.
What this could lead to
If successful, this could offer a safer, less invasive repair option for people with complex aortic aneurysms who are too high-risk for open surgery, potentially improving survival and quality of life.
What could go wrong
This is an early-stage study focused on safety and feasibility, not a proven treatment. Risks include major complications like stroke, kidney failure, or bowel ischemia, and the modified device may not work for everyone.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 200 people

The number the study aims to enrol. It can still change while the study runs.

Started

Sep 2021

Expected to finish

Sep 2028

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: 1. Age ≥ 18 years old 2. Life expectancy \> 2 year(s) 3. Patient is considered to be at high risk of morbidity and mortality with open surgical repair 4. A patient may be entered into the study if the patient has at least one of the following: * Juxtarenal, suprarenal or a thoracoabdominal aortic aneurysm with a diameter ≥ 5.5 cm or 2 times the normal aortic diameter * Aneurysm with a history of growth ≥ 0.5 cm per year * Saccular aneurysms deemed at significant risk for rupture based upon physician interpretation * Symptomatic juxtarenal, suprarenal or a thoracoabdominal aortic aneurysm * Thoracoabdominal aortic aneurysms secondary to aortic dissection meeting above criteria 5. Patient is considered to be at high risk of morbidity and mortality with open surgical repair 6. Iliac or femoral access vessel morphology that is compatible with vascular access techniques, devices or accessories, with or without use of a surgical conduit 7. Nonaneurysmal aortic segment proximal to the aneurysm (neck) with a: * Minimum neck length of 20mm * Diameter in the range of 21-38mm * Angle less than 60° relative to the axis of the aneurysm * Angle less than 60° relative to the axis of the suprarenal aorta 8. Minimum branch vessel diameter greater than 5 mm 9. Iliac artery distal fixation site greater than 10mm in length and diameter in the range of 8-21mm. Exclusion Criteria: 1. Under the age of 18 years 2. Can be treated in accordance with the instructions for use with a legally marketed endovascular prosthesis 3. Is eligible for enrollment in a manufacturer-sponsored IDE at the investigational site 4. Willing to participate in a sponsor-investigator IDE with access to a non-physician modified endovascular prostheses at the investigational site 5. Willing to travel to an investigational site with access to a non-physician modified endovascular prosthesis 6. Unwilling or unable to comply with the follow-up schedule 7. Inability or refusal to give informed consent by patient or legal representative 8. Patient is pregnant or breastfeeding 9. Life expectancy \< 2-years despite successful aneurysm exclusion 10. Free rupture with hemodynamic instability 11. Ongoing infection 12. Diagnosis of, or suspected connective tissue disease 13. Known sensitivities or allergies to the materials of construction of the devices 14. Known hypersensitivity or contraindication to anticoagulation or contrast media that cannot be adequately medically managed 15. Uncorrectable coagulopathy 16. Body habitus that would inhibit x-ray visualization of the aorta or exceeds the safe capacity of the equipment 17. Patient has had a major surgical or interventional procedure unrelated to the treatment of the aneurysm planned ≤ 30 days of the endovascular repair 18. Unstable angina (defined as angina with a progressive increase in symptoms, new onset at rest or nocturnal angina) 19. Systemic or local infection that may increase the risk of endovascular graft infection 20. Leaking or free rupture of aneurysm associated with hemodynamic instability. 21. Baseline creatinine greater than 3.0 mg/dL 22. Known history of, or suspected connective tissue disorders (e.g., Marfan Syndrome, Ehler's Danlos Syndrome) Anatomical exclusion criteria: 1. Inadequate femoral or iliac access compatible with the required delivery systems, not amenable to open surgical or endovascular conduit placement 2. Absence of a non-aneurysmal aortic segment for proximal seal zone with: * A diameter measured outer wall to outer wall of no greater than 38mm and no less than 21 mm; * Parallel aortic wall with \<20% diameter change and without significant calcification and/or thrombus in the selected area of seal zone 3. Visceral vessel anatomy not compatible with physician-modified Zenith® Alpha Endovascular Graft due to excessive occlusive disease or small size not amenable to stent graft placement 4. Unsuitable distal iliac artery fixation site and anatomy: * Common iliac artery fixation site diameter measured outer wall to outer wall on a sectional image (CT) \<8.0 mm with inability to perform open surgical conduit * Iliac artery diameter measured outer wall to outer wall on a sectional image (CT) \>21 mm at distal fixation site, with inability to perform open internal iliac artery revascularization or iliac branch stent graft * Iliac artery distal fixation site \<10 mm in length * Inability to preserve at least one hypogastric artery

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Juxtarenal aortic aneurysm are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    The full official record for this study. This one lists no contact details, but it is the first place any would appear.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • MedStar Washington Hospital Center

    Washington D.C., District of Columbia, 20010, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.